We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

6954:TSEFanuc Corporation Analysis

Data as of 2026-06-13 - not real-time

¥6,950.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Fanuc trades around ¥6,950, sitting just below its 20‑day SMA (¥7,674) but comfortably above the 200‑day SMA (¥5,834), suggesting a longer‑term bullish backdrop despite short‑term softness. Technical momentum is mixed: the RSI sits at ~42, indicating neutral‑to‑slightly bearish pressure, while the MACD histogram is negative and the signal line is bearish, flagging potential near‑term downside toward the identified support at ¥6,290.
Fundamentally, the company delivers solid revenue growth of ~10% YoY, healthy operating margins (~24%) and a robust cash pile exceeding ¥750 bn with zero net debt, supporting a 60% dividend payout and a sustainable yield of 1.5%. However, a trailing PE of ~39 versus an industry average of ~31 and a DCF fair‑value estimate around ¥4,345 signal that the stock is currently overvalued, with analysts pricing modest upside of roughly 6% (target ~¥7,380). The balance of strong cash generation, dividend sustainability, and modest upside makes Fanuc a candidate for a hold‑to‑buy stance, especially for investors with a medium‑ to long‑term horizon.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • Bearish MACD and RSI indicating limited near‑term momentum
  • Proximity to technical support at ¥6,290
  • Current price above short‑term SMA suggesting limited upside

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Solid revenue growth and strong operating margins
  • Sustainable dividend with 60% payout ratio
  • Analyst targets implying modest upside (~6%)

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust cash position and zero net debt enhancing financial resilience
  • Long‑term demand for automation and robotics in global manufacturing
  • Consistent profitability and dividend track record supporting total return

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin19.41%
P/E Ratio38.9
ROE9.35%
ROA5.70%
P/B Ratio3.5
Op. Cash Flow¥250.9B
Free Cash Flow¥159.5B
Industry P/E30.6

Technical Analysis

TrendBullish
RSI42.7
Support¥6,290.00
Resistance¥8,703.00
MA 20¥7,674.25
MA 50¥6,991.02
MA 200¥5,834.20
MACDBearish
VolumeStable
Fear & Greed Index89.86

Valuation

Fair Value¥4,344.83
Target Price¥7,379.50
Upside/Downside6.18%
GradeOvervalued
TypeBlend
Dividend Yield1.54%

Risk Assessment

Beta0.93
Volatility58.44%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.